Nevro this week announced it appointed Greg Siller as senior VP and chief commercial officer, effective June 19.
Siller will replace Niamh Pellegrini, who is leaving the company on June 9. He has spent the last 17 years at Stryker, where he held numerous roles of varying responsibility in sales and marketing. He most recently was VP and GM of the Stryker Interventional Spine business since January 2020.
“I am delighted to welcome Greg to the Nevro team,” CEO and President Kevin Thornal said in a news release. “For the last 17 years, Greg has led the development, implementation and execution of successful commercial strategies and programs for several Stryker businesses, including most recently Stryker’s Interventional Spine business. His proven track record of success and his passion for building high-performing commercial organizations will be instrumental as we continue to focus on accelerating revenue growth, developing underpenetrated markets such as painful diabetic neuropathy and non-surgical back pain, and launching new products, including our new HFX iQ system. I’m confident that Greg’s appointment will further bolster our ability to capitalize on the growth opportunities in front of us and accelerate our market performance. I also want to thank Niamh for her contributions over the last four years and wish her success in her future endeavors.”
The company also announced that in conjunction with the appointment, it is updating its revenue guidance for the second quarter of 2023 to be in the range of $106-108 million from its previous estimate of $110-112 million.
“Given where we now expect to finish the second quarter, we are taking the opportunity to update our second-quarter revenue guidance at this time. We will provide a more detailed discussion of our second quarter results and update our full-year 2023 guidance on our upcoming earnings call in August,” Thornal said.